Evaluating the effectiveness of biologics for chronic rhinosinusitis with nasal polyps

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the real-world efficacy of biologic treatments in patients diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP). Participants aged 18 and older who meet the reimbursement criteria for biologics will be included. The study will focus on patient-reported outcomes and nasal polyp scores measured through questionnaires and nasal endoscopy after 24 weeks of treatment. The goal is to better understand how these biologics perform in everyday clinical settings compared to standard treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participant must be at least 18 years of age at the time of signing the informed consent.
2. Capable of giving signed informed consent.
3. Participants should have CRSwNP.
4. Participants should fulfil the reimbursement criteria for their prescribed biological (omalizumab, mepolizumab and/or dupilumab).

Exclusion Criteria:

1\. Patients treated with other biological therapies in the 3 months prior to the current biological (this is not applicable to patients who are in the trial and switch biological).

Where it's running

• Onze Lieve Vrouw hospital Aalst
  Aalst, Belgium Recruiting
• General hospital Sint-Jan Bruges
  Bruges, Belgium Recruiting
• University hospital Saint-Luc
  Brussels, Belgium Recruiting
• University hospital of Antwerp
  Edegem, Belgium Recruiting
• Hospital Zuid-Oost Limburg
  Genk, Belgium Recruiting
• University Hospital Brussels
  Jette, Belgium Recruiting

Study contacts

• Principal investigator: Peter Hellings, MD,PhD — Universitaire Ziekenhuizen KU Leuven
• Study coordinator: Elien Borgers, MSc
• Email: elien.borgers@uzleuven.be
• Phone: 003216342037

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis with Nasal Polyps

  This study tests whether metabolic and immune markers in nasal tissue and blood differ between people with nasal polyps and those without, to help understand CRSwNP and find potential diagnostic clues.

  Recruiting Harran University · Sanliurfa, Şanlıurfa · NCT07860411

• Triamcinolone-loaded nanocapsules after endoscopic nasal surgery

  This trial tests whether a triamcinolone acetonide–loaded nanocapsule spray is better than saline irrigation for healing after endoscopic nasal surgery in adults with chronic rhinosinusitis and nasal polyps.

  Recruiting Phase 2 Deraya University · Minya, Menia Governorate · NCT07714525

• Smell training in CRS patients with smell loss

  This study tests whether a 3-month smell training program can improve smell function and related immune and mental health measures in adults with chronic rhinosinusitis and smell loss.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07681973

• Tezepelumab in real-world CRSwNP: a real-world look at patient outcomes

  This study tests tezepelumab in adults with chronic rhinosinusitis with nasal polyps to see how their symptoms and daily life change in routine care over about two years.

  Recruiting at 19 sites AstraZeneca · Berlin and 18 other locations · NCT07633158

• PROPEL corticosteroid‑releasing sinus implants — IBUKI cohort

  This project tests how safe and well PROPEL corticosteroid‑releasing sinus implants work for people in Japan with chronic rhinosinusitis who undergo endoscopic sinus surgery.

  Recruiting Medtronic · Asahikawa · NCT07546682

• BBT002 in healthy adults and in people with chronic rhinosinusitis with nasal polyps

  This study tests BBT002 versus placebo to see how it acts, how safe it is, and whether it helps people with chronic rhinosinusitis with nasal polyps, with or without asthma.

  Recruiting at 12 sites Phase 1/2 Bambusa Therapeutics · Beijing, Beijing Municipality and 11 other locations · NCT07436949

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.